Our History

  • 2016 – New international patent application.
  • 2015 – Orphan drug designation for Biliary tract cancer (EMA).
  • 2014 – First clinical trial of Redaporfin in head and neck cancer.
  • 2012-2013 – Safety pharmacology and toxicology GLP studies.
  • 2011-2012 – Nonclinical proof-of-concept studies with Redaporfin for PDT of cancer.
  • 2010 – Luzitin set-up. Licensing-in of initial IP from the University of Coimbra.

 

Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma